Literature DB >> 11238800

Historical perspective on garlic and cardiovascular disease.

K Rahman1.   

Abstract

Cardiovascular disease is a complex and multifactorial disease characterized by such factors as high cholesterol, hypertension, reduced fibrinolysis, increase in blood-clotting time and increased platelet aggregation. Dietary therapy is the first step in the treatment of hyperlipidemia; garlic has been used medicinally for centuries and is still included in the traditional medicine of many cultures. Historically, there has been great interest in the role of garlic in reducing cardiovascular risk factors. Evidence from numerous studies points to the fact that garlic can bring about the normalization of plasma lipids, enhancement of fibrinolytic activity, inhibition of platelet aggregation and reduction of blood pressure and glucose. However, some contradictory results have also emerged as a result of methodological shortcomings, the use of different formulations/preparations of garlic and different time scales of the studies. Accordingly, further clinical studies are required in which standardized formulations of garlic with known compositions can be used. Such formulations (e.g., Aged Garlic Extract) are now available and are being investigated. Evidence obtained from these studies indicates that garlic has potential in the prevention and control of cardiovascular disorders and is beneficial when taken as a dietary supplement.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11238800     DOI: 10.1093/jn/131.3.977S

Source DB:  PubMed          Journal:  J Nutr        ISSN: 0022-3166            Impact factor:   4.798


  30 in total

1.  High temperature- and high pressure-processed garlic improves lipid profiles in rats fed high cholesterol diets.

Authors:  Chan Wok Sohn; Hyunae Kim; Bo Ram You; Min Jee Kim; Hyo Jin Kim; Ji Yeon Lee; Dai-Eun Sok; Jin Hee Kim; Kun Jong Lee; Mee Ree Kim
Journal:  J Med Food       Date:  2012-03-09       Impact factor: 2.786

Review 2.  Molecular mechanisms and targets of cancer chemoprevention by garlic-derived bioactive compound diallyl trisulfide.

Authors:  Marie Lue Antony; Shivendra V Singh
Journal:  Indian J Exp Biol       Date:  2011-11       Impact factor: 0.818

3.  Diallyl trisulfide inhibits estrogen receptor-α activity in human breast cancer cells.

Authors:  Eun-Ryeong Hahm; Shivendra V Singh
Journal:  Breast Cancer Res Treat       Date:  2014-02-01       Impact factor: 4.872

4.  Effect of garlic supplementation on oxidized low density lipoproteins and lipid peroxidation in patients of essential hypertension.

Authors:  Veena Dhawan; Sanjay Jain
Journal:  Mol Cell Biochem       Date:  2004-11       Impact factor: 3.396

5.  Forkhead Box Q1 Is a Novel Target of Breast Cancer Stem Cell Inhibition by Diallyl Trisulfide.

Authors:  Su-Hyeong Kim; Catherine H Kaschula; Nolan Priedigkeit; Adrian V Lee; Shivendra V Singh
Journal:  J Biol Chem       Date:  2016-04-29       Impact factor: 5.157

Review 6.  Multitargeted prevention and therapy of cancer by diallyl trisulfide and related Allium vegetable-derived organosulfur compounds.

Authors:  Anna A Powolny; Shivendra V Singh
Journal:  Cancer Lett       Date:  2008-06-24       Impact factor: 8.679

Review 7.  Next-Gen Therapeutics for Skin Cancer: Nutraceuticals.

Authors:  Annapoorna Sreedhar; Jun Li; Yunfeng Zhao
Journal:  Nutr Cancer       Date:  2018-05-15       Impact factor: 2.900

8.  A review of studies of garlic (Allium sativum) on serum lipids and blood pressure before and after 1994: does the amount of allicin released from garlic powder tablets play a role?

Authors:  Marc P McRae
Journal:  J Chiropr Med       Date:  2005

9.  In vitro assessment of oxidative stress and apoptotic mechanisms of garlic extract in the treatment of acute promyelocytic leukemia.

Authors:  Clement G Yedjou; Paul B Tchounwou
Journal:  J Cancer Sci Ther       Date:  2012-01-01

10.  Anti-inflammatory and arthritic effects of thiacremonone, a novel sulfur compound isolated from garlic via inhibition of NF-kappaB.

Authors:  Jung Ok Ban; Ju Hoon Oh; Tae Myoung Kim; Dae Joong Kim; Heon-Sang Jeong; Sang Bae Han; Jin Tae Hong
Journal:  Arthritis Res Ther       Date:  2009-09-30       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.